Article
Oncology
Kimiharu Takamatsu, Ryuichi Mizuno, Yuto Baba, Yota Yasumizu, Nobuyuki Tanaka, Suguru Shirotake, Toshikazu Takeda, Shinya Morita, Kazuhiro Matsumoto, Takeo Kosaka, Hiroshi Asanuma, Masafumi Oyama, Shuji Mikami, Mototsugu Oya
Summary: The study found that on-treatment CRP control could serve as a predictive factor for the efficacy of nivolumab in refractory mRCC patients, with patients in the CRP control group showing significantly longer PFS.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Oncology
Yusuke Yano, Takaya Ohno, Kazumasa Komura, Wataru Fukuokaya, Taizo Uchimoto, Takahiro Adachi, Yosuke Hirasawa, Takeshi Hashimoto, Atsuhiko Yoshizawa, Shogo Yamazaki, Satoshi Tokushige, Kazuki Nishimura, Takuya Tsujino, Keita Nakamori, Shutaro Yamamoto, Kosuke Iwatani, Fumihiko Urabe, Keiichiro Mori, Takafumi Yanagisawa, Shunsuke Tsuduki, Kiyoshi Takahara, Teruo Inamoto, Jun Miki, Takahiro Kimura, Yoshio Ohno, Ryoichi Shiroki, Haruhito Azuma
Summary: This study evaluated the predictive value of serum CRP level for metastatic renal cell carcinoma treated with first-line ipilimumab and nivolumab. The results indicated that patients with CRP >1 mg/dL had significantly shorter survival than those with CRP <1 mg/dL, regardless of ccRCC or nccRCC.
Article
Gastroenterology & Hepatology
Toshimitsu Iwasaki, Satoshi Nara, Yoji Kishi, Minoru Esaki, Takeshi Takamoto, Kazuaki Shimada
Summary: This study aimed to establish a reliable criterion for early drain removal after pancreaticoduodenectomy based on predictive factors of clinically relevant postoperative pancreatic fistula available on postoperative day 3. The two-factor criterion developed in the study showed a reliable predictive ability and was considered safe for early drain removal in patients who met the criteria.
JOURNAL OF GASTROINTESTINAL SURGERY
(2021)
Article
Urology & Nephrology
Melis Guer, Andreas Janitzky, Martin Schostak
Summary: This study evaluated the impact of changes in C-reactive protein (CRP) levels and the early onset of treatment-related adverse events (TRAEs) on the treatment response in advanced renal cell carcinoma (aRCC) patients. Patients were stratified into low-risk, intermediate-risk, and high-risk groups based on CRP kinetics and TRAEs. The results showed a significantly increased risk of disease progression in patients without CRP response and TRAEs.
WORLD JOURNAL OF UROLOGY
(2023)
Article
Oncology
Yaoting Zhang, Dongsheng Gu
Summary: This study found that pretreatment serum CRP level is associated with prognosis in patients with head and neck squamous cell carcinoma. Patients with high CRP level had worse survival outcomes, and CRP level is correlated with N1-3 stage and prognosis.
FRONTIERS IN ONCOLOGY
(2022)
Article
Medicine, Research & Experimental
Qi Wang, Jiaju Xu, Zhiyong Xiong, Tianbo Xu, Jingchong Liu, Yuenan Liu, Jiaping Chen, Jian Shi, Yi Shou, Changjie Yue, Di Liu, Huageng Liang, Hongmei Yang, Xiong Yang, Xiaoping Zhang
Summary: This research identified that several CENP family members, especially CENPA, are highly expressed in ccRCC tissues and can serve as biomarkers for the disease. Overexpression of CENPA was found to promote ccRCC proliferation and metastasis by accelerating the cell cycle and activating the Wnt/beta-catenin signaling pathway. Targeting CENPA with selective drugs may be a promising direction for cancer treatment.
JOURNAL OF TRANSLATIONAL MEDICINE
(2021)
Article
Immunology
Niklas Klumper, Philipp Schmucker, Oliver Hahn, Benedikt Hoh, Angelika Mattigk, Severine Banek, Jorg Ellinger, Julia Heinzelbecker, Danijel Sikic, Markus Eckstein, Arne Strauss, Friedemann Zengerling, Michael Holzel, Philip Zeuschner, Charis Kalogirou
Summary: The study validated the predictive potential of early CRP kinetics in first-line immunotherapy for mRCC. CRP responders, especially CRP flare-responders, showed significantly prolonged progression-free survival compared to non-CRP responders.
CLINICAL & TRANSLATIONAL IMMUNOLOGY
(2021)
Article
Genetics & Heredity
Suhua Gao, Lei Yan, Hongtao Zhang, Xiaoguang Fan, Xiaojing Jiao, Fengmin Shao
Summary: The study identified differentially expressed genes (DEGs) between primary and metastatic ccRCC tumors through integrated genomic and transcriptomic analysis, showing enrichment in pathways such as ECM-receptor interaction, platelet activation, protein digestion absorption, focal adhesion, and the PI3K-Akt signaling pathway. DEGs associated with tumor immune infiltrates and tumor mutation burden were found to be more likely to lead to poor prognosis of ccRCC. Seven core genes were significantly upregulated in metastatic tumors compared to primary tumors, potentially serving as novel therapeutic and early diagnostic biomarkers of ccRCC.
FRONTIERS IN GENETICS
(2021)
Article
Oncology
Benjamin N. Schmeusser, Henry Biermann, Edouard H. Nicaise, Adil A. Ali, Dattatraya H. Patil, Eric Midenberg, Talia Helman, Manuel Armas-Phan, Reza Nabavizadeh, Shreyas S. Joshi, Vikram M. Narayan, Mehmet A. Bilen, Sarah P. Psutka, Kenneth Ogan, Viraj A. Master
Summary: This study evaluates the association between low creatinine to cystatin-C ratio (Cr/Cys-C) and overall survival (OS) and recurrence-free survival (RFS) in patients with renal cell carcinoma (RCC) treated with nephrectomy. The results suggest that low Cr/Cys-C is associated with inferior oncologic outcomes and may serve as a serum biomarker for the presence of sarcopenia in this patient population.
Article
Oncology
Elisa Kankkunen, Patrick Penttila, Katriina Peltola, Petri Bono
Summary: This study evaluated the prognostic role of elevated C-reactive protein (CRP) values and immune-related adverse events (irAEs) in indicating the efficacy of immune checkpoint inhibitors (ICIs) in metastatic renal cell carcinoma (mRCC) patients. The results showed that elevated baseline CRP, on-treatment CRP, and absence of irAE were associated with poor outcomes in nivolumab-treated mRCC patients.
Article
Oncology
Ahmad Y. Y. Abuhelwa, Joaquim Bellmunt, Ganessan Kichenadasse, Ross A. A. McKinnon, Andrew Rowland, Michael J. J. Sorich, Ashley M. M. Hopkins
Summary: C-reactive protein (CRP) is a powerful prognostic marker for predicting survival in patients with metastatic renal cell carcinoma (mRCC) treated with immunotherapy, with superior predictive ability compared to the International Metastatic RCC Database Consortium (IMDC) model.
FRONTIERS IN ONCOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Koji Iinuma, Risa Tomioka-Inagawa, Koji Kameyama, Tomoki Taniguchi, Kei Kawada, Takashi Ishida, Shingo Nagai, Torai Enomoto, Shota Ueda, Makoto Kawase, Shinichi Takeuchi, Kota Kawase, Daiki Kato, Manabu Takai, Keita Nakane, Takuya Koie
Summary: A multicenter retrospective study evaluated the efficacy and safety of cabozantinib in patients with advanced or metastatic renal cell carcinoma. The study found that cabozantinib is a useful treatment option for mRCC patients and may benefit from earlier use. Additionally, high CRP levels may be a poor prognostic factor in patients treated with cabozantinib, requiring careful follow-up.
Article
Oncology
Xinlong Zheng, Longfeng Zhang, Lin Wu, Jun Zhao, Jianguo Sun, Yong Fang, Jin Zhou, Qian Chu, Yihong Shen, Zhenzhou Yang, Lijin Chen, Meijuan Huang, Xiaoyan Lin, Zhenhua Liu, Peng Shen, Zhijie Wang, Xin Wang, Huijuan Wang, Zhengbo Han, Anwen Liu, Hongmei Zhang, Feng Ye, Wen Gao, Fang Wu, Zhengbo Song, Shengchi Chen, Chenzhi Zhou, Qian Wang, Chunwei Xu, Dingzhi Huang, Xiaobin Zheng, Qian Miao, Kan Jiang, Yiquan Xu, Shiwen Wu, Haibo Wang, Qiuyu Zhang, Shanshan Yang, Yujing Li, Sihui Chen, Gen Lin
Summary: This study investigated the predictive value of baseline CRP levels on the efficacy of chemotherapy plus immune checkpoint inhibitors in patients with advanced LSCC. The results showed that elevated CRP levels were associated with a reduction in treatment efficacy in the combination therapy group.
Article
Oncology
Mark Stares, Vishwani Chauhan, Jigi Moudgil-Joshi, Qiu G. Kong, Jahangeer Malik, Aravindhan Sundaramurthy, Tony Elliott, Edward Mains, Steve Leung, Alexander Laird, Stefan N. Symeonides
Summary: A study has found that initial active surveillance (AS) is an appropriate management option for selected patients with metastatic renal cell carcinoma (mRCC). C-reactive protein (CRP), a biomarker of systemic inflammation, may provide additional objective information to assist clinical decision-making in mRCC patients being considered for initial AS.
Article
Oncology
Yuri Kalinin, Ivan Jose Correia-Neto, Suellen Vieira do Nascimento, Vanessa Cristina de Branco Goncaves, Bruno Augusto Benevenuto de Andrade, Cassiano Francisco Weege Nonaka, Pollianna Muniz Alves, John Lennon Silva Cunha
Summary: Metastases in the oral cavity are rare and associated with poor prognosis. We reported a rare metastatic ccRCC in a 58-year-old female presenting as a painless nodule on the tongue mimicking a benign lesion. The definitive diagnosis was metastatic ccRCC, and despite treatment with sunitinib, the disease progressed and palliative care was initiated. Clinician's experience in identifying oral metastatic lesions can reveal undiagnosed primary tumors and provide better prognosis and survival rates.